

Title	Exploring the concept of functional vitamin D deficiency in pregnancy: impact of the interaction between 25-hydroxyvitamin D and parathyroid hormone on perinatal outcomes
Authors	Hemmingway, Andrea;Kenny, Louise C.;Malvisi, Lucio;Kiely, Mairead E.
Publication date	2018
Original Citation	Hemmingway, A., Kenny, L. C., Malvisi, L. and Kiely, M. E. (2018) 'Exploring the concept of functional vitamin D deficiency in pregnancy: impact of the interaction between 25-hydroxyvitamin D and parathyroid hormone on perinatal outcomes', The American Journal of Clinical Nutrition, 108(4), pp. 821-829. doi: 10.1093/ajcn/nqy150
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://dx.doi.org/10.1093/ajcn/nqy150 - 10.1093/ajcn/nqy150
Rights	© 2018 American Society for Nutrition. Published by Oxford University Press. This is a pre-copyedited, author-produced version of an article accepted for publication in American Journal of Clinical Nutrition following peer review. The version of record, 108, Issue 4, 1 October 2018, Pages 821–829, is available online at: https://doi.org/10.1093/ajcn/nqy150
Download date	2024-05-13 18:48:33
Item downloaded from	https://hdl.handle.net/10468/7296



UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Exploring the concept of functional vitamin D deficiency in pregnancy: impact of the interaction between 25-hydroxyvitamin D and parathyroid hormone on perinatal outcomes

Andrea Hemmingway^{1,2}, Louise C Kenny³, Lucio Malvisi^{1,2}, Mairead E Kiely^{1,2*}

¹Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Cork, Ireland (AH, LM, MEK)

²The Irish Centre for Fetal and Neonatal Translational Research (INFANT), University College Cork, Cork, Ireland (AH, LCK, LM, MEK)

³Department of Women's and Children's Health, University of Liverpool, United Kingdom (LCK)

Authors' last names for indexing: Hemmingway, Kenny, Malvisi, Kiely

Disclaimers: The authors have no disclaimers.

***Corresponding author:** Professor Mairead Kiely, Cork Centre for Vitamin D and Nutrition Research, Room 127, Level 1, Food Science Building, University College Cork, Western Road, Cork, Ireland, +353 214903394, m.kiely@ucc.ie

Sources of Support: This study and LM were supported by a grant to MEK from the European Commission for the Integrated Project ODIN (Food-based Solutions for Optimal Vitamin D Nutrition and Health through the Lifecycle, GA613977). The SCOPE Ireland pregnancy cohort study was funded by a grant to LCK from the Health Research Board of Ireland (CSA 02/2007). AH is supported by Science Foundation Ireland funding to MEK for COMBINE (INFANT/B3067), which is co-funded by the European Regional Development Fund (ERDF) under Ireland's European Structural and Investment Funds Programmes 2014-

2020. MEK is a principal investigator in the Science Foundation Ireland funded INFANT Research Centre (grant no. 12/RC/2272).

Short running head: Vitamin D, parathyroid hormone and pregnancy

Number of Tables: 4

Number of Figures: 1

Trial registration: The SCOPE pregnancy cohort is registered at the Australian, New Zealand Clinical Trials Registry (<http://www.anzctr.org.au>), ID: ACTRN12607000551493.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BP, blood pressure; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MAP, mean arterial pressure; PTH, parathyroid hormone; SCOPE, Screening for Pregnancy Endpoints study; SGA, small-for-gestational-age

Abstract (298 words)

Background: Associations of vitamin D with perinatal outcomes are inconsistent and few have considered the wider calcium metabolic system.

Objective: To explore functional vitamin D deficiency in pregnancy by investigating associations between vitamin D status, parathyroid hormone and perinatal outcomes.

Design: SCOPE (Screening for Pregnancy Endpoints) Ireland is a prospective cohort study of low risk, nulliparous pregnant women. We measured serum 25-hydroxyvitamin D [25(OH)D] and parathyroid hormone [PTH] at 15 weeks' gestation in 1754 participants.

Results: Mean \pm SD 25(OH)D was 56.6 ± 25.8 nmol/L (22.7 ± 10.3 ng/mL) and geometric mean (95% CI) PTH was 7.84 (7.7, 8.0) pg/mL [0.86 (0.85, 0.88) pmol/L]. PTH was elevated in 34.3% of women who had 25(OH)D <30 nmol/L and in 13.9% of those with 25(OH)D ≥ 75 nmol/L. While 17% had 25(OH)D <30 nmol/L, 5.5% had functional vitamin D deficiency, defined as 25(OH)D <30 nmol/L plus elevated PTH. Elevated mean arterial pressure (MAP), gestational hypertension, preeclampsia and small-for-gestational-age (SGA) birth were confirmed in 9.2%, 11.9%, 3.8% and 10.6% of participants, respectively. In fully adjusted regression models, neither low 25(OH)D nor elevated PTH alone increased risk of any individual outcome. The prevalence of elevated MAP (19.1% vs. 9.7%) and SGA (16.0% vs. 6.7%) were highest ($P < 0.05$) in those with functional vitamin D deficiency compared to the reference [25(OH)D ≥ 75 nmol/L and normal PTH]. The adjusted prevalence ratio (PR) and relative risk (RR) (95% CIs) for elevated MAP and SGA were 1.83 (1.02, 3.27) and 1.53 (0.80, 2.93), respectively. There was no effect of functional vitamin D deficiency on the risk of gestational hypertension [adjusted RR (95% CI); 1.00 (0.60, 1.67)] or preeclampsia [adjusted RR (95% CI); 1.17 (0.32, 4.20)].

24 **Conclusions:** The concept of functional vitamin D deficiency, reflecting calcium metabolic
25 stress, should be considered in studies of vitamin D in pregnancy.

26 **Key words:** Vitamin D, 25-hydroxyvitamin D, parathyroid hormone, pregnancy, perinatal,
27 mean arterial pressure, gestational hypertension, preeclampsia, small-for-gestational-age

Accepted Manuscript

Introduction

Pregnancy represents a period of particular nutritional vulnerability for the mother and developing fetus and nutritional deficits can adversely affect perinatal outcomes. Low vitamin D status [assessed by blood levels of 25-hydroxyvitamin D (25(OH)D)] in pregnancy is prevalent worldwide, in Caucasian and other ethnicities (1-3). Although low 25(OH)D has been associated with adverse perinatal outcomes including preeclampsia and small-for-gestational-age (SGA) birth (4, 5), there is inconsistency in the literature (6). Vitamin D classically functions as part of the calcium metabolic system which maintains serum calcium within a critical narrow physiological window (7). Despite this long recognised metabolic connection, vitamin D and calcium are most often considered in isolation in terms of perinatal outcomes, with a lack of consideration for interactive effects (8). Although attenuated, the inverse relationship between 25(OH)D and calciotropic parathyroid hormone (PTH) is maintained in pregnancy in spite of the many changes in vitamin D and calcium metabolism (9). Secondary hyperparathyroidism refers to elevation of PTH resulting from low 25(OH)D and/or low calcium intake (10) and represents functional vitamin D deficiency. Scholl and colleagues described the concept of calcium metabolic stress in pregnancy, in which adverse effects of vitamin D deficiency are mediated through a functional impact on the calcium metabolic system (assessed by measurement of PTH) (11, 12). To the best of our knowledge, these associations have not been replicated in a large, well-characterized pregnancy cohort. We aimed to test the concept of calcium metabolic stress by exploring associations of 25(OH)D, PTH and functional vitamin D deficiency at 15 weeks' gestation with adverse perinatal outcomes, including elevated mean arterial pressure (MAP), gestational hypertension, preeclampsia and SGA birth in a large cohort of low risk pregnant women.

Subjects and Methods

Study design and participants

The Screening for Pregnancy Endpoints (SCOPE) study (www.scopestudy.net), an international, multi-center, prospective cohort study was designed with the primary aim of developing screening tests to predict adverse pregnancy outcomes, with preeclampsia as the primary outcome variable (13). SCOPE Ireland recruited 1792 participants who were attending antenatal care at Cork University Maternity Hospital, Cork, Ireland (51.9°N) between March 2008 and February 2011. Full clinical and methodological study details have been published previously (13). In summary, nulliparous women were eligible for inclusion provided the pregnancy was a low risk singleton pregnancy at less than 16 weeks' gestation. Exclusion criteria included pregnancies at increased risk of preeclampsia, SGA or spontaneous preterm birth due to specific underlying medical conditions or medical history, known major fetal anomaly or abnormal karyotype and interventions that could modify the outcome of pregnancy, such as aspirin treatment.

Extensive data on family situation, lifestyle and demographics, including current smoking, alcohol and drug use, supplement use, activity, employment and medical history were collected by trained research midwives. As a pre-pregnancy measurement was not possible, and given the well-established systematic bias in self-report of weight and height, maternal height and weight at 15 weeks' gestation were measured for calculation of BMI (14). Two consecutive blood pressure (BP) measurements were taken using a mercury or aneroid sphygmomanometer and proteinuria was assessed by semi-quantitative automated dip-stick reading. All demographic, anthropometric and clinical data were entered into a secure internet deployed database (MedSciNet AB, Stockholm, Sweden). Non-fasting blood samples were collected, processed to serum and stored at -80°C within 4 hours of collection.

SCOPE was conducted in accordance with the Declaration of Helsinki guidelines and ethical approval was obtained from the Clinical Research Ethics Committee of the Cork Teaching Hospitals [ECM5(10)05/02/2008]. SCOPE is registered at the Australian, New Zealand Clinical Trials Registry (<http://www.anzctr.org.au>), ID: ACTRN12607000551493. Written informed consent was provided by all participants at commencement of the study, which was on average, at 15 weeks of gestation.

Clinical definition of outcomes

Perinatal outcomes were precise and predefined (13), with participants followed prospectively throughout pregnancy and delivery. MAP was calculated from systolic and diastolic BP measurements as $\text{diastolic BP} + [(\text{systolic BP} - \text{diastolic BP})/3]$, with $\text{MAP} > 90$ mmHg denoting elevated MAP. Gestational hypertension was defined as a systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg on at least two occasions four hours apart after 20 weeks' of gestation but before the onset of labor. Preeclampsia was gestational hypertension with either proteinuria (24 hour urinary protein ≥ 300 mg or spot urine protein:creatinine ratio ≥ 30 mg/mmol creatinine or urine dipstick protein $\geq 2+$) or any multi-system complication of preeclampsia. SGA birth was defined as a birth weight $< 10^{\text{th}}$ customized centile adjusted for maternal height, booking weight and ethnicity as well as gestation at delivery and infant sex (15).

Biochemical Analysis

Serum 25(OH)D

Measurement of 25(OH)D in our laboratory has been detailed previously (16). Briefly, total 25(OH)D was calculated by summation of individually quantified 25(OH)D₂ and 25(OH)D₃. Serum 25(OH)D₂ and 25(OH)D₃ concentrations were measured in using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a Waters Acquity UPLC

system coupled to an Acquity Triple Quadrupole (TQD)[®] mass spectrometer detector (Waters, Milford, USA). Four levels of serum-based NIST (National Institute of Standards and Technology) certified quality assurance material (SRM 972) were used for method validation while quality control materials assayed in parallel to all samples were purchased from Chromsystems (Munich, Germany). NIST calibrators (SRM 2972) were used throughout the analysis. The limit of detection (LoD) for 25(OH)D₃ and 25(OH)D₂ was 0.31 and 0.44 nmol/L, respectively. The limit of quantitation (LoQ) for 25(OH)D₃ and 25(OH)D₂ was 1.03 and 1.43 nmol/L, respectively. Intra- and inter- assay CVs for both metabolites were < 6% and < 5% respectively. The laboratory of the Cork Centre for Vitamin D and Nutrition Research is accredited by the CDC Vitamin D Standardization Certification program and participates in the Vitamin D External Quality Assessment Scheme (DEQAS) (Charring Cross Hospital, London, UK).

Serum PTH

Serum intact PTH was measured using an ELISA (MD Biosciences Inc., Minnesota, USA) on the automated Dynex DS2[®] ELISA processing platform (Dynex Technologies, Virginia, USA). This two-site assay is designed to measure biologically intact PTH 1-84 and utilizes two purified goat polyclonal antibodies, each specific to a distinct region on the PTH molecule. A biotinylated antibody binds to mid-region and C-terminal PTH 39-84. The detection antibody, a horseradish peroxidase conjugated antibody, binds N-terminal PTH 1-34. PTH was measured in duplicate in 1497 participants and in singular in a further 257 participants as serum volume was insufficient for duplicate measurement. Geometric mean PTH concentration did not differ between duplicate and single measurements (independent samples t-test, $P = 0.10$) and single and duplicate measurements were collated for analysis, giving a total of 1754 PTH measurements. Intra- and inter- assay CVs for intact PTH were < 5% and < 7% respectively.

Statistical analysis

Statistical analysis was performed using IBM SPSS® version 22.0 (IBM Corp., Armonk, NY, USA) and SAS® version 9.4 (SAS Institute Inc., Cary, NC, USA) software for Windows™. A full dataset, with no missing information, was available for all participants ($n = 1754$) and analysis was carried out without imputation. PTH was natural log-transformed to an approximately normal distribution and log PTH was used in analysis. Descriptive statistics were prepared for participants and independent samples t-test or ANOVA were used as appropriate to assess differences in mean concentrations of 25(OH)D and PTH within maternal characteristics. Post-hoc comparisons used Bonferroni correction. 25(OH)D is reported as mean \pm SD and PTH as geometric mean (95% CI). The 25(OH)D/PTH relationship was graphically depicted by a scatter plot with Lowess curve (locally weighted regression smoothing scatterplot). ANOVA with Bonferroni corrected post-hoc analysis was performed to assess PTH concentrations across categories of 25(OH)D. Occurrence of adverse outcomes was compared between 25(OH)D/PTH categories using Chi-square tests (or Fisher's test as appropriate).

Associations between predictors and outcomes were assessed by log-Poisson regression, with regression models constructed to examine the effects of low 25(OH)D and elevated PTH, both individually and in combination, on adverse outcomes. While the full distribution of 25(OH)D was explored, and 25(OH)D and PTH were described across the range of 25(OH)D values, we considered low vitamin D status as 25(OH)D < 30 nmol/L (7) and replete status ≥ 75 nmol/L (17). These categories were used in regression models to allow simple comparison between groups of interest i.e. those with a low and replete vitamin D status. In the absence of pregnancy-specific reference ranges, we defined elevated PTH as greater than the 80th percentile. However, to minimize potential influence of undiagnosed pathological conditions relating to PTH, we excluded the top 2.5% of PTH concentrations. Thus, participants with

PTH between the 80th and 97.5th percentiles were classed as having elevated PTH. Reference groups were 25(OH)D \geq 75 nmol/L and normal PTH (i.e. PTH \leq 80th percentile). Non-white participants ($n = 40$) were excluded from regression models.

Separate log-Poisson regression models (12 in total) were built for each predictor-outcome association based on both statistical goodness of fit of the model and clinical and theoretical knowledge. To circumvent the problem of large standard errors obtained with standard Poisson regression, we used Zou's modified Poisson approach which leads to the estimation of robust error variance and produces correct confidence intervals (18). To obtain best fit models the following steps were taken. Univariable analysis was used to assess the association between each potential covariate and the outcome of interest, with inclusion based on significance at $\alpha = 0.25$. A multivariable model including all significant covariates from the univariate analysis was constructed. The association of interaction terms with each outcome was examined, and interaction terms were included in multivariable models if significant (at $\alpha = 0.10$) and clinically meaningful. To support the statistical model building process clinical and theoretical knowledge of established associations between variables along with directed acyclic graphs (DAGs) were used to develop a theoretical framework of covariate-predictor-outcome relationships and to determine the role of each covariate (e.g. confounder, intermediate, collider) in the model, aiding in decision making during model development. This process resulted in an individual best-fit log-Poisson regression model for each of the 12 predictor-outcome models. Although all associations were examined using the same modified log-Poisson approach detailed above, because 25(OH)D, PTH and MAP were measured at the same time point associations are presented as prevalence ratios (PR) and 95% CIs while associations of 25(OH)D and PTH with gestational hypertension, preeclampsia and SGA are expressed as relative risks (RR) and 95% CIs.

Results

Descriptive results

Participant characteristics and 25(OH)D and PTH concentrations in the SCOPE Ireland pregnancy cohort ($n = 1754$) are shown in **Table 1**. Mean \pm SD 25(OH)D concentration was 56.62 ± 25.8 nmol/L (22.7 ± 10.3 ng/mL) and geometric mean (95% CI) PTH was 7.84 (7.7, 8.0) pg/mL [0.86 (0.85, 0.88) pmol/L]. This predominantly white (97.7%) cohort had a mean \pm SD age of 30.5 ± 4.5 years and BMI of 24.9 ± 4.2 kg/m². At 15 weeks of gestation, 10.0% and 16.4% of participants, respectively, reported current smoking and alcohol consumption. Multi-nutrient supplements were consumed by 40% of participants and this was associated with significantly higher 25(OH)D and lower PTH concentrations in consumers ($P < 0.001$ for both). White ethnicity was also associated with higher 25(OH)D and lower PTH than other ethnicities ($P \leq 0.001$ for both). Although season of entry was significantly associated with 25(OH)D concentration ($P < 0.001$), PTH did not change with season. PTH increased and 25(OH)D decreased with increasing BMI category at 15 weeks of gestation; however post-hoc analysis revealed a significant decrease in 25(OH)D only in obese participants (BMI ≥ 30 kg/m²) compared to those with a normal BMI. PTH concentration was highest in the small proportion of participants (1.2%) with a BMI < 18.5 kg/m². Mean arterial pressure was 79.1 ± 7.6 mmHg and 9.2% of participants had elevated MAP (> 90 mmHg). The prevalence of gestational hypertension, preeclampsia and SGA in the cohort were 11.9%, 3.8% and 10.6%, respectively.

Associations of 25(OH)D, PTH and functional vitamin D deficiency with perinatal outcomes

The lowess curve in **Figure 1** illustrates a decrease in PTH across a broad range of increasing 25(OH)D concentrations, with a decline in rate of decrease evident between 40 - 50 nmol/L. **Table 2** depicts PTH concentrations across the distribution of 25(OH)D, showing that PTH

decreased significantly with increasing 25(OH)D ($P < 0.001$). Elevated PTH occurred more commonly ($P < 0.05$) in participants with 25(OH)D < 30 nmol/L (34.3%) than those ≥ 75 nmol/L (13.9%). In terms of vitamin D status, 44% of women had 25(OH)D < 50 nmol/L and 17% were below 30 nmol/L, while 25% were had 25(OH)D ≥ 75 nmol/L. In the stratified analysis of 25(OH)D and PTH, the prevalence of functional vitamin D deficiency, defined as 25(OH)D < 30 nmol/L plus PTH $> 80^{\text{th}}$ percentile, was much lower, at 5.5%, with 11.4% having a 25(OH)D < 50 nmol/L plus PTH $> 80^{\text{th}}$ percentile.

Associations of 25(OH)D, PTH and 25(OH)D/PTH groupings with elevated MAP are shown in **Table 3**. The prevalence of elevated MAP was not significantly higher (12.0% versus 9.3%) in participants with 25(OH)D < 30 nmol/L compared with 25(OH)D ≥ 75 nmol/L ($P > 0.05$). While there was an association of elevated PTH with elevated MAP [PR (95% CI); 1.49 (1.08, 2.04)], this trend was attenuated with covariate adjustment. Stratification of participants by 25(OH)D/PTH, shown in Table 3, revealed a prevalence of elevated MAP of 19.1% in those with functional vitamin D deficiency compared with 9.7% in the reference group [25(OH)D ≥ 75 nmol/L and normal PTH] ($P < 0.05$), translating to an adjusted PR (95% CI) of 1.83 (1.02, 3.27). Prevalence of elevated MAP did not increase with 25(OH)D < 30 nmol/L if PTH was not elevated [adjusted PR (95% CI); 0.91 (0.50, 1.65)].

Table 4 shows the associations of 25(OH)D, PTH and 25(OH)D/PTH groupings with gestational hypertension, preeclampsia and SGA birth. Having a 25(OH)D < 30 nmol/L increased the risk of SGA in crude but not adjusted analysis. There was no association of elevated PTH with gestational hypertension, preeclampsia or SGA. In combined 25(OH)D/PTH groupings, the prevalence of gestational hypertension was highest with elevated PTH and did not vary with 25(OH)D (both 18%, $P > 0.05$). Having functional vitamin D deficiency did not increase risk of gestational hypertension compared to the

reference, which was $25(\text{OH})\text{D} \geq 75 \text{ nmol/L}$ with normal PTH [adjusted RR (95% CI); 1.00 (0.60, 1.67)].

The lowest prevalence of preeclampsia (1.9%) was in those with $25(\text{OH})\text{D} \geq 75 \text{ nmol/L}$ and normal PTH, compared to 5.0% when $25(\text{OH})\text{D} \geq 75 \text{ nmol/L}$ with elevated PTH ($P > 0.05$).

In those with $25(\text{OH})\text{D} < 30 \text{ nmol/L}$, the prevalence of preeclampsia did not differ depending on PTH status ($P > 0.05$). Occurrence of preeclampsia was not significantly increased (4.3% versus 1.9%) with functional vitamin D deficiency compared to the reference group ($P > 0.05$) [adjusted RR (95% CI); 1.17 (0.32, 4.20)].

The proportion of participants with a SGA newborn in the reference group (6.7%) was lower than any other group, while 16% of those with functional vitamin D deficiency had a SGA birth ($P < 0.05$). A 2-fold increase in risk [RR (95% CI); 2.38 (1.31, 4.33)] was attenuated [adjusted RR (95% CI); 1.53 (0.80, 2.93)] in a fully adjusted model including BMI, smoking, university education, job status, recreational walking and multi-nutrient supplementation. A $25(\text{OH})\text{D}$ concentration $\geq 30 - < 75 \text{ nmol/L}$ with elevated PTH was not associated with SGA or any other outcome (data not shown). Regression models were repeated for all outcomes using a $25(\text{OH})\text{D}$ cut-off of $< 50 \text{ nmol/L}$; no associations were observed in multivariate models (data not shown).

Discussion

Inconsistencies in associations of maternal vitamin D status and perinatal outcomes are multifactorial (4, 5, 19) but it is likely that calcium-vitamin D interactions, largely ignored, could be a critical consideration (8, 11, 12). In this largest study to date of $25(\text{OH})\text{D}$, PTH and pregnancy outcomes, we report a two-fold increased prevalence ratio of elevated MAP in women with functional vitamin D deficiency, defined by $25(\text{OH})\text{D} < 30 \text{ nmol/L}$ and elevated

PTH, versus those with $25(\text{OH})\text{D} \geq 75$ nmol/L and normal PTH. This increase was present with low vitamin D status only if PTH was concurrently elevated. A similar trend was observed for SGA, although this was attenuated in regression models. Functional vitamin D deficiency did not increase risks of gestational hypertension or preeclampsia, although prevalence of preeclampsia was lowest, at 1.9%, in the reference group.

Our analysis follows earlier analyses by Scholl et al (11, 12), who reported that women with functional vitamin D deficiency and calcium metabolic stress were two-three-fold more likely to develop preeclampsia and SGA. Mixed parity women recruited to their multi-ethnic (86% black or Hispanic) study were generally young (69% < 25 years of age) and of low socioeconomic status (11, 12). We aimed to extend the concept of functional vitamin D deficiency to a prospective cohort of well-characterized women in Northern Europe.

Participants in the SCOPE Ireland cohort were nulliparous with low risk pregnancies, generally well-educated, mostly white and 89% were ≥ 25 years of age. In this cohort, as in the literature (20), clear differences in both $25(\text{OH})\text{D}$ and PTH were evident between white and other ethnicities, highlighting the need for explorations of vitamin D and the calcium metabolic system that are specified by ethnicity. Thus, we restricted our current analysis to white participants as the numbers of other ethnic groups were too small to analyze separately.

The prevalence of low vitamin D status in our cohort was higher than in many cohorts at similar latitude, reflective of the lack of a mandated maternal supplementation policy, analytical sensitivity and accuracy as well as inclement prevailing weather (16). Given that we previously observed a reduction in the combined prevalence of preeclampsia+SGA with $25(\text{OH})\text{D} \geq 75$ nmol/L (16) we chose this as the reference value for $25(\text{OH})\text{D}$ and defined low $25(\text{OH})\text{D}$ status as < 30 nmol/L (7). There is a lack of clarity with regard to PTH threshold levels in pregnancy, as PTH decreases in early gestation (21), reducing the applicability of non-pregnancy thresholds. In this context, and given the population specific

274 nature of PTH (22), as well as well-documented, substantial analytical differences between
275 methods (23-27), we used a percentile cut-off, which although crude, may best capture
276 elevated PTH at a sample specific level. Additionally, we excluded the top 2.5% of PTH
277 values to minimise the risk of including undiagnosed cases of primary hyperparathyroidism,
278 which may have produced artificially elevated outcome risks. Although sample specific, there
279 may be some potential for misclassification of participants with use of a percentile cut-off as
280 a result of inherent inter-individual variation in PTH. Concentrations of PTH were lower in
281 our cohort than other studies (9, 11, 28, 29), but direct comparison is difficult; analytical
282 method, gestation and ethnicity influence PTH, as do specimen type (30) and BMI (31).

283 High PTH has been associated with blood pressure (32, 33) and cardiovascular risk indicators
284 (34), and there are a number of biologically plausible mechanisms through which the calcium
285 metabolic system may impact blood pressure. Belizán et al proposed that high PTH increases
286 intracellular calcium, triggering contraction of vascular smooth muscle cells and
287 vasoconstriction (35). Evidence of inter-play between the calcium metabolic system and
288 renin-angiotensin-aldosterone system is accumulating (36). Hemodynamics can be explored
289 through a range of measures and because a meta-analysis ($n = 60,599$) reported a second
290 trimester MAP > 90 mmHg to be predictive of preeclampsia (37) we investigated this
291 outcome in addition to gestational hypertension and preeclampsia. Although we report that
292 those with functional vitamin D deficiency were two-fold more likely to have elevated MAP
293 at 15 weeks' gestation, there was no increase in risk of gestational hypertension. Given that
294 25(OH)D, PTH and MAP were all measured at 15 weeks' gestation, this may reflect a time-
295 point specific occurrence. Elevated MAP and gestational hypertension are not mutually
296 inclusive outcomes; in this cohort 36% of those with elevated MAP at 15 weeks' developed
297 gestational hypertension and these outcomes may reflect different health profiles. Gestational

hypertension can occur at any stage in the second half of pregnancy and requires close monitoring and treatment as clinically indicated (38).

Considering preeclampsia, the effect of vitamin D supplementation is not clear (19, 39). However, combined vitamin D and calcium supplementation significantly reduced risk of preeclampsia in three trials of 1,114 women (19). None of these trials compared each nutrient individually versus combined supplementation and placebo. In a cohort in which 6% developed preeclampsia, Scholl et al reported that participants with functional vitamin D deficiency at < 20 weeks' gestation were three times more likely to develop preeclampsia (11). Despite a substantially larger sample size, we did not replicate this effect, potentially due to analytical differences and our application of a refined estimate of elevated PTH in a 'trimmed' distribution. The inclusion criteria for SCOPE, focusing on women with low risk pregnancies, likely resulted in a different disease profile in those who developed preeclampsia between the two cohorts; a relevant consideration given potential differences in beneficial effects of vitamin D and calcium dependent on disease type and risk profile (40, 41). However, the lowest prevalence of preeclampsia occurred in those with $25(\text{OH})\text{D} \geq 75$ nmol/L with normal PTH, indicating a potential benefit of higher serum $25(\text{OH})\text{D}$, as suggested by Aghajafari et al (4), particularly if PTH is not elevated.

With regards to SGA, fetal skeletal development represents a potential mechanism through which perturbations in the maternal calcium metabolic system could predispose to SGA (42, 43) and interactions between vitamin D and calcium on fetal bone growth have been noted in pregnant adolescents (44), a unique group due to dual growth requirements. Elevated blood pressure can also predispose to SGA birth, both in association with and independently of preeclampsia (45-47). Causative effects of vitamin D and calcium on fetal growth and SGA have not been definitively established (39, 41, 48, 49). Observational evidence suggests associations of both dairy intakes and PTH with fetal growth (50-52). A secondary analysis

of trial data in Gambian women, found no synergistic effect of calcium supplementation and 25(OH)D on fetal growth (53). There was little evidence of vitamin D deficiency in the Gambian population who had low habitual calcium intakes, and these data may not be applicable in our setting with prevalent vitamin D deficiency. In our analysis we did not distinguish between SGA neonates born constitutionally small and those with fetal growth restriction resulting in SGA, in whom outcomes may be worse (54).

To our knowledge, this is the largest study to investigate vitamin D and PTH in the context of pregnancy and perinatal outcomes. Our data are strengthened by use of clinically defined outcomes and the gold standard technique of CDC-accredited LC-MS/MS for measurement of 25(OH)D. However, we did not have access to calcium intake data; this would have enabled a more specific examination of calcium metabolic stress and perinatal outcomes, although inclusion of PTH may capture some variation resulting from differences in calcium intake. Harmonization and standardization of PTH analysis is required to define reference ranges for pregnancy and for the purposes of this field, to better describe the 25(OH)D/PTH relationship during gestation. In the absence of these data, the clinical significance of elevated PTH is difficult to interpret.

In summary, prevalence of SGA was highest with functional vitamin D deficiency and we have demonstrated evidence of functional vitamin D deficiency and elevated MAP, reflecting the adverse impact of stress to the maternal calcium metabolic system in women at 15 weeks of gestation. Though challenging in design and resource allocation, consideration should be given to a priori inclusion of calcium intakes as well as quality-assured 25(OH)D and PTH measurement in future studies of vitamin D and perinatal health.

Acknowledgements

The authors' responsibilities were as follows: MEK designed the research, is the ODIN and COMBINE grant-holder and guarantor of the manuscript; LCK is the SCOPE PI globally and has overall responsibility for the SCOPE Ireland pregnancy cohort; AH conducted the PTH sample analysis and data analysis; LM conducted statistical analysis and drafted the statistical methodology; AH and MEK wrote the manuscript and MEK was responsible for the final content. All authors read and approved the final draft of the manuscript. None of the authors reported a conflict of interest related to the study.

References

1. Leffelaar ER, Vrijkotte TG, van Eijsden M. Maternal early pregnancy vitamin D status in relation to fetal and neonatal growth: results of the multi-ethnic Amsterdam Born Children and their Development cohort. *Br J Nutr* 2010;104:108-17.
2. Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM. High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. *J Nutr* 2007;137:447-52.
3. Saraf R, Morton SM, Camargo CA Jr., Grant CC. Global summary of maternal and newborn vitamin D status - a systematic review. *Matern Child Nutr* 2016;12:647-68.
4. Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O'Beirne M, Rabi DM. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. *BMJ* 2013;346:f1169.
5. Thorne-Lyman A, Fawzi WW. Vitamin D during pregnancy and maternal, neonatal and infant health outcomes: a systematic review and meta-analysis. *Paediatr Perinat Epidemiol* 2012;26:75-90.
6. Brannon PM, Picciano MF. Vitamin D in pregnancy and lactation in humans. *Annu Rev Nutr* 2011;31:89-115.
7. Institute of Medicine. Dietary reference intakes for Calcium and Vitamin D. Washington (DC): National Academies Press, 2011.
8. Kiely M, Hemmingway A, O'Callaghan KM. Vitamin D in pregnancy: current perspectives and future directions. *Ther Adv Musculoskelet Dis* 2017;9:145-54.
9. Hamilton SA, McNeil R, Hollis BW, Davis DJ, Winkler J, Cook C, Warner G, Bivens B, McShane P, Wagner CL. Profound vitamin D deficiency in a diverse group of women during pregnancy living in a sun-rich environment at latitude 32°N. *Int J Endocrinol* 2010;917428.
10. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. *Endocr Rev* 2001;22:477-501.
11. Scholl TO, Chen X, Stein TP. Vitamin D, secondary hyperparathyroidism, and preeclampsia. *Am J Clin Nutr* 2013;98:787-93.
12. Scholl TO, Chen X, Stein TP. Maternal calcium metabolic stress and fetal growth. *Am J Clin Nutr* 2014;99:918-25.
13. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, McCowan LM, Simpson NA, Dekker GA, Roberts CT, et al. Early pregnancy prediction of preeclampsia

- in nulliparous women, combining clinical risk and biomarkers: the Screening for Pregnancy Endpoints (SCOPE) international cohort study. *Hypertension* 2014;64:644-52.
14. Engstrom JL, Paterson SA, Doherty A, Trabulsi M, Speer KL. Accuracy of self-reported height and weight in women: an integrative review of the literature. *J Midwifery Womens Health* 2003;48:338-45.
 15. McCowan L, Stewart AW, Francis A, Gardosi J. A customised birthweight centile calculator developed for a New Zealand population. *Aust N Z J Obstet Gynaecol* 2004;44:428-31.
 16. Kiely ME, Zhang JY, Kinsella M, Khashan AS, Kenny LC. Vitamin D status is associated with uteroplacental dysfunction indicated by pre-eclampsia and small-for-gestational-age birth in a large prospective pregnancy cohort in Ireland with low vitamin D status. *Am J Clin Nutr* 2016;104:354-61.
 17. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96:1911-30.
 18. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *Am J Epidemiol* 2004;159:702-6.
 19. De-Regil LM, Palacios C, Lombardo LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev* 2016;1:CD008873.
 20. Gutiérrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. *Osteoporos Int* 2011;22:1745-53.
 21. Møller UK, Streym S, Mosekilde L, Heickendorff L, Flyvbjerg A, Frystyk J, Jensen LT, Rejnmark L. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. *Osteoporos Int* 2013;24:1307-20.
 22. Souberbielle JC, Brazier F, Piketty ML, Cormier C, Minisola S, Cavalier E. How the reference values for serum parathyroid hormone concentration are (or should be) established? *J Endocrinol Invest* 2017;40:241-56.
 23. Worth GK, Vasikaran SD, Retallack RW, Musk AA, Gutteridge DH. Major method-specific differences in the measurement of intact parathyroid hormone: studies in patients with and without chronic renal failure. *Ann Clin Biochem* 2004;41:149-54.
 24. Cantor T, Yang Z, Caraianni N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. *Clin Chem* 2006;52:1771-6.

25. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. *Kidney Int* 2006;70:345-50.
26. Sukumar D, Shapses S, Partridge NC, Schneider S. Intervariability among serum intact parathyroid hormone assays: a need for standardization. *Osteoporos Int* 2008;19:1805-6.
27. Cavalier E, Delanaye P, Vranken L, Bekaert AC, Carlisi A, Chapelle JP, Souberbielle JC. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. *Nephrol Dial Transplant* 2012;27:1950-6.
28. Morley R, Carlin JB, Pasco JA, Wark JD. Maternal 25-hydroxyvitamin D and parathyroid hormone concentrations and offspring birth size. *J Clin Endocrinol Metab* 2006;91:906-12.
29. Haddow JE, Neveux LM, Palomaki GE, Lambert-Messerlian G, Canick JA, Grenache DG, Lu J. The relationship between PTH and 25-hydroxy vitamin D early in pregnancy. *Clin Endocrinol (Oxf)* 2011;75:309-14.
30. Glendenning P, Laffer LL, Weber HK, Musk AA, Vasikaran SD. Parathyroid hormone is more stable in EDTA plasma than in serum. *Clin Chem* 2002;48:766-7.
31. Aloia JF, Feuerman M, Yeh JK. Reference range for serum parathyroid hormone. *Endocr Pract* 2006;12:137-44.
32. Kim H, Chung YE, Jung SC, Im H, Yang SY, Kim DY, Jeong E, Kim B, Park SK. Independent associations of circulating 25-hydroxyvitamin D and parathyroid hormone concentrations with blood pressure among Koreans: The Korea National Health and Nutrition Examination Survey (KNHANES), 2009-2010. *Calcif Tissue Int* 2013;93:549-55.
33. Snijder MB, Lips P, Seidell JC, Visser M, Deeg DJ, Dekker JM, van Dam RM. Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. *J Intern Med* 2007;261:558-65.
34. Bosworth C, Sachs MC, Duprez D, Hoofnagle AN, Ix JH, Jacobs DR Jr., Peralta CA, Siscovick DS, Kestenbaum B, de Boer IH. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. *Clin Endocrinol (Oxf)* 2013;79:429-36.
35. Belizán JM, Villar J, Repke J. The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence. *Am J Obstet Gynecol* 1988;158:898-902.
36. Vaidya A, Brown JM, Williams JS. The renin-angiotensin-aldosterone system and calcium-regulatory hormones. *J Hum Hypertens* 2015;29:515-21.
37. Cnossen JS, Vollebregt KC, de Vrieze N, ter Riet G, Mol BW, Franx A, Khan KS, van der Post JA. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. *BMJ* 2008;336:1117-20.

38. National Institute for Health and Clinical Excellence. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press 2010. Updated 2017.
39. Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. *BMJ* 2017;359:j5237.
40. Dror DK. Vitamin D status during pregnancy: maternal, fetal, and postnatal outcomes. *Curr Opin Obstet Gynecol* 2011;23:422-6.
41. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev* 2014;6:CD001059.
42. Dror DK, King JC, Fung EB, Van Loan MD, Gertz ER, Allen LH. Evidence of associations between feto-maternal vitamin D status, cord parathyroid hormone and bone-specific alkaline phosphatase, and newborn whole body bone mineral content. *Nutrients* 2012;4:68-77.
43. Beltrand J, Alison M, Nicolescu R, Verkauskiene R, Deghmoun S, Sibony O, Sebag G, Lévy-Marchal C. Bone mineral content at birth is determined both by birth weight and fetal growth pattern. *Pediatr Res* 2008;64:86-90.
44. Young BE, McNanley TJ, Cooper EM, McIntyre AW, Witter F, Harris ZL, O'Brien KO. Maternal vitamin D status and calcium intake interact to affect fetal skeletal growth in utero in pregnant adolescents. *Am J Clin Nutr* 2012;95:1103-12.
45. Block-Abraham DM, Adamovich D, Turan OM, Doyle LE, Blitzer MG, Baschat AA. Maternal blood pressures during pregnancy and the risk of delivering a small-for-gestational-age neonate. *Hypertens Pregnancy* 2016;35:350-60.
46. Wikström AK, Gunnarsdottir J, Nelander M, Simic M, Stephansson O, Cnattingius S. Prehypertension in pregnancy and risks of small for gestational age infant and stillbirth. *Hypertension* 2016;67:640-6.
47. Anderson NH, Sadler LC, Stewart AW, Fyfe EM, McCowan LM. Independent risk factors for infants who are small for gestational age by customised birthweight centiles in a multi-ethnic New Zealand population. *Aust N Z J Obstet Gynaecol* 2013;53:136-42.
48. Harvey NC, Holroyd C, Ntani G, Javaid K, Cooper P, Moon R, Cole Z, Tinati T, Godfrey K, Dennison E, et al. Vitamin D supplementation in pregnancy: a systematic review. *Health Technol Assess* 2014;18:1-190.
49. Buppasiri P, Lumbiganon P, Thinkhamrop J, Ngamjarus C, Laopaiboon M, Medley N. Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes. *Cochrane Database Syst Rev* 2015;2:CD007079.

50. Chang SC, O'Brien KO, Nathanson MS, Caulfield LE, Mancini J, Witter FR. Fetal femur length is influenced by maternal dairy intake in pregnant African American adolescents. *Am J Clin Nutr* 2003;77:1248-54.
51. Mannion CA, Gray-Donald K, Koski KG. Association of low intake of milk and vitamin D during pregnancy with decreased birth weight. *CMAJ* 2006;174:1273-7.
52. Brunvand L, Quigstad E, Urdal P, Haug E. Vitamin D deficiency and fetal growth. *Early Hum Dev* 1996;45:27-33.
53. Prentice A, Jarjou LM, Goldberg GR, Bennett J, Cole TJ, Schoenmakers I. Maternal plasma 25-hydroxyvitamin D concentration and birthweight, growth and bone mineral accretion of Gambian infants. *Acta Paediatr* 2009;98:1360-2.
54. Alberry M, Soothill P. Management of fetal growth restriction. *Arch Dis Child Fetal Neonatal Ed* 2007;92:F62-7.

Table 1

Sample characteristics, PTH and 25(OH)D concentrations in the SCOPE Ireland pregnancy cohort ($n = 1754$)¹

Characteristic	%	25(OH)D		PTH	
		Concentration (nmol/L)	<i>P</i>	Concentration (pg/mL)	<i>P</i>
All participants		56.62 ± 25.8	-	7.84 (7.7, 8.0)	-
Ethnicity			< 0.001		0.001
White	97.7	57.11 ± 25.8		7.79 (7.6, 8.0)	
Other	2.3	35.54 ± 19.9		10.28 (8.5, 12.5)	
Age (years)			< 0.001		0.15
< 25	11.5	49.38 ± 27.8		7.66 (7.1, 8.2)	
≥ 25 - < 30	30.3	58.47 ± 26.5 ²		7.91 (7.6, 8.3)	
≥ 30 - < 35	45.0	57.88 ± 24.8 ²		7.69 (7.4, 8.0)	
≥ 35	13.2	54.33 ± 24.8		8.38 (7.8, 9.0)	
BMI (kg/m ²) ³			0.017		0.005 ⁴
< 18.5	1.2	54.39 ± 29.0		9.77 (7.1, 13.5)	
≥ 18.5 - < 25	58.4	58.14 ± 26.3		7.58 (7.4, 7.8)	
≥ 25 - < 30	28.1	55.30 ± 25.2		8.14 (7.8, 8.5)	
≥ 30	12.3	52.62 ± 24.3 ⁵		8.28 (7.7, 8.9)	
Smoking status ³			< 0.001		0.08
No	90.0	57.66 ± 25.8		7.90 (7.7, 8.1)	
Yes	10.0	47.23 ± 24.4		7.34 (6.8, 7.9)	
Alcohol consumption ³			0.10		0.47
No	83.6	56.17 ± 25.9		7.81 (7.6, 8.0)	
Yes	16.4	58.91 ± 25.5		8.00 (7.6, 8.5)	
Multi-nutrient supplementation ³			< 0.001		< 0.001
No	60.1	48.70 ± 23.8		8.15 (7.9, 8.4)	
Yes	39.9	68.54 ± 24.2		7.40 (7.1, 7.7)	
Season of entry ⁶			< 0.001		0.16

Winter	58.4	49.54 ± 24.6	7.96 (7.7, 8.2)	
Summer	41.6	66.57 ± 24.2	7.68 (7.4, 8.0)	
Elevated MAP ³			0.42	0.10
No	90.8	57.28 ± 25.6	7.73 (7.5, 7.9)	
Yes	9.2	55.61 ± 27.2	8.35 (7.6, 9.1)	
Gestational Hypertension			0.85	0.62
No	88.1	56.57 ± 25.8	7.82 (7.6, 8.0)	
Yes	11.9	56.93 ± 26.1	7.99 (7.4, 8.7)	
Preeclampsia			0.18	0.28
No	96.2	57.27 ± 25.8	7.77 (7.6, 8.0)	
Yes	3.8	52.97 ± 23.8	8.34 (7.3, 9.5)	
Small-for-gestational-age			0.003	0.16
No	89.4	57.74 ± 26.0	7.75 (7.5, 7.9)	
Yes	10.6	51.85 ± 23.3	8.20 (7.6, 8.9)	

¹PTH, geometric mean (95% CI) (all such values); 25(OH)D, mean ± SD (all such values). Differences assessed using independent samples t-test for binary variables and ANOVA for variables with multiple categories. Post-hoc analysis used Bonferroni correction. PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; SCOPE, Screening for Pregnancy Endpoints; MAP, mean arterial pressure.

² $P < 0.05$ compared to lowest group.

³At 15 week visit.

⁴Overall ANOVA significant but no significant between group differences after Bonferroni correction.

⁴ $P < 0.05$ compared to BMI ≥ 18.5 - < 25 kg/m².

⁶Winter: November through May and Summer: June through October.

Table 2PTH concentration by 25(OH)D category in the SCOPE Ireland pregnancy cohort ($n = 1754$)¹

25(OH)D (nmol/L)	%	PTH (pg/mL)
< 30	17.3	9.80 (9.2, 10.4) ^{3,4}
≥ 30 - < 40	13.6	8.50 (8.0, 9.1) ^{2,3,4}
≥ 40 - < 50	13.2	7.80 (7.3, 8.4) ^{2,4}
≥ 50 - < 75	30.7	7.54 (7.2, 7.9) ^{2,4}
≥ 75	25.2	6.78 (6.5, 7.1) ^{2,3}

¹PTH geometric mean (95% CI) (all such values).

Differences assessed using ANOVA. Overall *P*-trend for ANOVA, $P < 0.001$. Post hoc analysis used Bonferroni correction. PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; SCOPE, Screening for Pregnancy Endpoints.

² $P < 0.05$ compared with < 30 nmol/L.³ $P < 0.05$ compared with 50 - 75 nmol/L.⁴ $P < 0.05$ compared with ≥ 75 nmol/L.

Table 3

Association of 25(OH)D and PTH with elevated MAP in white participants of the SCOPE Ireland pregnancy cohort¹

25(OH)D (nmol/L)	PTH (percentile)	n	%	Elevated MAP (> 90 mmHg)	
				Unadjusted	Adjusted
≥ 75	—	441	9.3	Reference	Reference
< 30	—	283	12.0	1.29 (0.84, 1.99)	1.46 (0.90, 2.38) ²
—	≤ 80 th	1338	9.3	Reference	Reference
—	> 80 th	334	13.8	1.49 (1.08, 2.04)	1.28 (0.94, 1.75) ³
≥ 75	≤ 80 th	373	9.7	Reference	Reference
≥ 75	> 80 th	60	8.3	0.86 (0.35, 2.11)	0.89 (0.34, 2.28) ⁴
< 30	≤ 80 th	180	8.3	0.86 (0.49, 1.53)	0.91 (0.50, 1.65) ⁴
< 30	> 80 th	94	19.1	1.98 (1.18, 3.33)	1.83 (1.02, 3.27) ⁴

¹Values are PRs (95% CIs). Log-Poisson regression was used to examine the association between 25(OH)D and PTH thresholds (individually and in combination) and risk of elevated MAP. 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; MAP, mean arterial pressure; SCOPE, Screening for Pregnancy Endpoints.

²25(OH)D-MAP model adjusted for BMI, maternal age, university education and supplementation.

³PTH-MAP model adjusted for BMI, maternal age, smoking, supplementation, recreational walking and alcohol consumption.

⁴25(OH)D/PTH-MAP model adjusted for BMI, maternal age, smoking, supplementation and recreational walking.

Table 4

Associations of 25(OH)D and PTH with gestational hypertension, preeclampsia and SGA in white participants of the SCOPE Ireland pregnancy cohort¹

25(OH)D (nmol/L)	PTH (percentile)	n	Gestational Hypertension			Preeclampsia			Small-for-gestational-age		
			%	Unadjusted	Adjusted	%	Unadjusted	Adjusted	%	Unadjusted	Adjusted
≥ 75	—	441	14.3	Reference	Reference	2.3	Reference	Reference	7.3	Reference	Reference
< 30	—	283	12.7	0.89 (0.61, 1.30)	0.76 (0.51, 1.13) ²	4.9	2.18 (0.98, 4.84)	1.06 (0.42, 2.68) ³	13.1	1.80 (1.15, 2.82)	1.18 (0.70, 1.99) ⁴
—	≤ 80 th	1338	11.3	Reference	Reference	3.7	Reference	Reference	10.3	Reference	Reference
—	> 80 th	334	14.7	1.30 (0.96, 1.75)	1.18 (0.87, 1.59) ⁵	4.5	1.20 (0.68, 2.11)	1.13 (0.63, 2.00) ⁶	10.8	1.05 (0.74, 1.48)	1.00 (0.71, 1.43) ⁷
≥ 75	≤ 80 th	373	13.7	Reference	Reference	1.9	Reference	Reference	6.7	Reference	Reference
≥ 75	> 80 th	60	18.3	1.34 (0.74, 2.42)	1.24 (0.62, 2.50) ⁸	5.0	2.66 (0.71, 10.02)	2.36 (0.68, 8.22) ⁹	11.7	1.74 (0.79, 3.85)	1.72 (0.77, 3.88) ¹⁰
< 30	≤ 80 th	180	10.0	0.73 (0.44, 1.21)	0.61 (0.37, 1.02) ⁸	5.0	2.66 (1.01, 7.04)	1.32 (0.45, 3.87) ⁹	10.6	1.57 (0.89, 2.78)	0.97 (0.52, 1.81) ¹⁰
< 30	> 80 th	94	18.1	1.32 (0.80, 2.18)	1.00 (0.60, 1.67) ⁸	4.3	2.27 (0.68, 7.58)	1.17 (0.32, 4.20) ⁹	16.0	2.38 (1.31, 4.33)	1.53 (0.80, 2.93) ¹⁰

¹Values are RRs (95% CIs). Log-Poisson regression was used to examine the association between 25(OH)D and PTH (individually and in combination) and risk of gestational hypertension, preeclampsia and SGA. 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; SGA, small-for-gestational-age; SCOPE, Screening for Pregnancy Endpoints.

²25(OH)D-gestational hypertension model adjusted for BMI, smoking and recreational walking.

³25(OH)D-preeclampsia model adjusted for BMI, university education, and supplementation.

⁴25(OH)D-SGA model adjusted for university education, job status, supplementation and recreational walking.

⁵PTH-gestational hypertension model adjusted for BMI, smoking, supplementation, moderate exercise and infant sex.

⁶PTH-preeclampsia adjusted for BMI, university education, supplementation, moderate exercise and infant sex.

⁷PTH-SGA model adjusted for BMI, university education, job status, smoking and moderate exercise.

⁸25(OH)D/PTH-gestational hypertension model adjusted for BMI and recreational walking.

⁹25(OH)D/PTH-preeclampsia model adjusted for BMI, university education and supplementation.

¹⁰25(OH)D/PTH-SGA model adjusted for BMI, smoking, university education, job status, supplementation and recreational walking.




Figure 1. Scatterplot with Lowess curve of log parathyroid hormone and 25-hydroxyvitamin D in participants of the SCOPE Ireland pregnancy cohort ($n = 1754$).